Characterizing olfaction, anxiety, and depression in subjective cognitive decline
- PMID: 40754807
- DOI: 10.1177/13872877251363422
Characterizing olfaction, anxiety, and depression in subjective cognitive decline
Abstract
BackgroundOlfactory dysfunction and neuropsychiatric symptoms are well-established hallmarks of Alzheimer's disease (AD) and serve as predictors of progression from mild cognitive impairment to AD. However, the literature remains unclear on whether olfactory dysfunction is already evident in the prodromal form of subjective cognitive decline (SCD).ObjectiveThis study aimed to characterize olfactory function and neuropsychiatric symptoms, including anxiety and depression, in individuals with SCD compared to healthy controls (HC).MethodsA total of 110 community-dwelling participants aged 60 years and older were recruited, with 59 classified as SCD (42 women) and 51 as HC (35 women). Participants completed validated anxiety and depression questionnaires (Geriatric Anxiety Inventory and Geriatric Depression Scale) and underwent a comprehensive olfactory assessment using the complete Sniffin' Sticks battery (odor threshold, discrimination, and identification).ResultsThe SCD group exhibited lower global olfactory scores (small to moderate effect size; Cohen's d = 0.41), and higher depression (large effect size; Cohen's d = 1.07) and anxiety (moderate effect size; Cohen's d = 0.64) scores compared to HC. Notably, global olfactory performance enhanced group status prediction and classification (SCD versus HC) when combined with anxiety and depression measures.ConclusionsThese findings highlight subtle but significant lower olfactory performance in individuals with SCD. The neurophysiological underpinnings are unclear and may be unveiled with electrophysiological methods such as olfactory-evoked potentials.
Keywords: Alzheimer's disease; anxiety; depression; olfaction; subjective cognitive decline.
Similar articles
-
Characterization of subclinical depressive and anxiety symptoms in older adults with subjective cognitive decline progressing to objective cognitive impairment: A prospective 4-year follow-up study.J Alzheimers Dis. 2025 Apr;104(3):720-731. doi: 10.1177/13872877251319538. Epub 2025 Mar 17. J Alzheimers Dis. 2025. PMID: 40091588 Free PMC article.
-
Predicting cognitive decline: Deep-learning reveals subtle brain changes in pre-MCI stage.J Prev Alzheimers Dis. 2025 May;12(5):100079. doi: 10.1016/j.tjpad.2025.100079. Epub 2025 Feb 6. J Prev Alzheimers Dis. 2025. PMID: 39920001 Free PMC article.
-
Investigation and analysis of mental health status of the older adult in western rural areas.Front Public Health. 2025 Jul 16;13:1612600. doi: 10.3389/fpubh.2025.1612600. eCollection 2025. Front Public Health. 2025. PMID: 40740371 Free PMC article.
-
Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment.Cochrane Database Syst Rev. 2024 Nov 5;11(11):CD001747. doi: 10.1002/14651858.CD001747.pub4. Cochrane Database Syst Rev. 2024. PMID: 39498781
-
Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases.Cochrane Database Syst Rev. 2024 Sep 12;9(9):CD015383. doi: 10.1002/14651858.CD015383.pub2. Cochrane Database Syst Rev. 2024. PMID: 39260823
LinkOut - more resources
Full Text Sources